Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On January 27, 2021, the Board of Directors (the “Board”) of Evelo Biosciences, Inc. (the “Company”) appointed John A. Hohneker, M.D. as a Class III director on the Board, effective immediately, to serve until the Company’s annual meeting of stockholders to be held in 2021 and until his successor is duly elected and qualified or his earlier death, disqualification, resignation or removal. Dr. Hohneker also was appointed a member of the Compensation Committee (the “Compensation Committee”) and the Science and Technology Committee (the “Science Committee”) of the Board.
Dr. Hohneker has served as the President and Chief Executive Officer of Anokion SA, a biotechnology company, since January 2018. Prior to joining Anokion, Dr. Hohneker was the president of research and development at FORMA Therapeutics Inc., a biotechnology company, from 2017 to 2018, and its executive vice president, head of research and development from 2015 to 2017. Prior to FORMA, he held roles of increasing responsibility at Novartis AG, most recently as senior vice president and global head of development for immunology and dermatology, and GlaxoWellcome. Dr. Hohneker received his B.A. in chemistry from Gettysburg College and his M.D. from the University of Medicine and Dentistry of New Jersey at Rutgers Robert Wood Johnson Medical School.
Dr. Hohneker is eligible to participate in the Company’s previously disclosed Non-Employee Director Compensation Program (the “NEDCP”), which provides for (i) an annual retainer of $35,000 for his service on the Board, (ii) an initial award of an option to purchase 31,380 shares of the Company’s common stock (the “Initial Award”) for his service on the Board, (iii) an annual retainer of $5,000 for his service on the Compensation Committee, (iv) an annual retainer of $4,000 for his service on the Science Committee and (v) following each annual meeting of the Company’s stockholders, an annual award of an option to purchase 15,690 shares of the Company’s common stock (the “Subsequent Award”), subject to the conditions set forth in the NEDCP. The Initial Award has an exercise price equal to $16.65 per share, the fair market value of a share of the Company’s common stock on the date of grant, and will vest and become exercisable in substantially equal monthly installments over three years following the grant date, subject to Dr. Hohneker’s continued service on the Board through each such vesting date. The Subsequent Awards vest and become exercisable on the earlier of the first anniversary of the grant date or the day immediately prior to the next annual meeting of the Company’s stockholders following the grant date, subject to Dr. Hohneker’s continued service on the Board through such vesting date. Dr. Hohneker is expected to enter into the Company’s standard indemnification agreement for directors and officers.